EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Surveillance vs Standard Surgery and Cost-Effectiveness After Neoadjuvant Chemoradiotherapy for Esophageal Cancer

Sanjiv S G Gangaram Panday, David van Klaveren, Sjoerd M Lagarde, Berend J van der Wilk, Ben M Eyck, Camiel Rosman, Bo J Noordman, Maria J Valkema, Tanya M Bisseling, Peter-Paul L O Coene, Jan Willem T Dekker, Marc J van Det und 26 weitere

JAMA Network Open · 27.07.2026 · 9 (7) · e2624615

DOI: 10.1001/jamanetworkopen.2026.24615 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 27.07.2026. Verfasst von Sanjiv S G Gangaram Panday und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Neoadjuvant Therapy, Watchful Waiting, Chemoradiotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Active surveillance is noninferior to standard surgery for 2-year survival and improves short-term health-related quality of life among patients with a complete clinical response (CCR) after neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer. Although active surveillance reduces the upfront costs of surgery and hospital stay, it requires repeated diagnostic tests and, for some patients, delayed surgery and hospitalization during follow-up.

Objective

To assess the cost-effectiveness of active surveillance compared with standard surgery after nCRT. Design, Setting, and Participants This prespecified cost-effectiveness analysis from a health care perspective conducted at 12 hospitals in the Netherlands as a secondary analysis of the Surgery as Needed for Oesophageal Cancer (SANO) trial, a noninferiority, cluster randomized study, enrolled patients with esophageal cancer who achieved a CCR after nCRT between November 8, 2017, and January 17, 2021, with follow-up for up to 5 years. Data were analyzed on June 1, 2025.

Interventions

Active surveillance, consisting of repeated response evaluations at 6, 9, 12, 16, 20, 24, 30, 36, 48, and 60 months after nCRT, compared with standard surgery. Main Outcome and Measures Incremental cost-effectiveness of active surveillance vs standard surgery and quality-adjusted life-years (QALYs) with 95% CIs up to 5 years were derived with bootstrapping, with 80% of patients (247 of 309) having complete follow-up. Incremental net monetary benefit (iNMB) was calculated at varying willingness-to-pay thresholds. All analyses followed the modified intention-to-treat principle. Costs are given in Euros (currency exchange rate of €1 = US $1.16 as of June 11, 2026).

Results

Among 309 patients (198 in the active surveillance group; median age, 69 years [IQR, 63-74 years]; 156 men [79%]; and 111 in the standard surgery group; median age, 68 years [IQR, 61-73 years]; 86 men [77%]), those in the active surveillance group had a mean of 2.99 QALYs (95% CI, 2.73-3.26) at 5 years vs 2.88 QALYs (95% CI 2.69-3.06) in the standard surgery group. Mean health care costs per patient at 5 years were €36 733 (95% CI, €33 530-€40 009) in the active surveillance group vs €45 106 (95% CI, €39 449-€51 545) in the standard surgery group. The incremental QALY for active surveillance was 0.11 (95% CI, −0.10 to 0.33) and mean costs were €8374 lower (95% CI, €1792-€15 355) compared with standard surgery. At a willingness-to-pay threshold of €80 000 per QALY, the mean iNMB was €17 568 (95% CI, −€725 to €37 497), indicating that active surveillance is cost-effective. Bootstrap analysis showed that 97% of replications fell in the cost-effective region. Conclusions and Relevance In this secondary analysis of a randomized clinical trial of patients with esophageal cancer achieving a CCR after nCRT, active surveillance was cost-effective over a 5-year horizon compared with standard surgery. Broader implementation of this strategy among appropriately selected patients would most likely reduce health care costs without compromising health outcomes. Trial Registration The Dutch Trial Register: NTR 6803

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsNeoadjuvant TherapyWatchful WaitingChemoradiotherapyHumansCost-Benefit AnalysisCost-Effectiveness AnalysisMaleFemaleMiddle AgedNetherlandsAgedQuality-Adjusted Life YearsQuality of Life

Autor:innen und Institutionen

  • Department of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.
  • Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Surgery, Maasstad Hospital, Rotterdam, the Netherlands.
  • Department of Surgery, Reinier de Graaf Gasthuis, Delft, the Netherlands.

Zitieren

APA

Gangaram Panday, S. S. G., van Klaveren, D., Lagarde, S. M., van der Wilk, B. J., Eyck, B. M., Rosman, C., Noordman, B. J., Valkema, M. J., Bisseling, T. M., Coene, P. L. O., Dekker, J. W. T., van Det, M. J., van Dieren, J. M., Doukas, M., van Esser, S., Fiets, W. E., Hartgrink, H. H., Heisterkamp, J., Hol, L., …, & Surgery as Needed for Oesophageal Cancer (SANO) Study Group (2026). Surveillance vs Standard Surgery and Cost-Effectiveness After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. JAMA Network Open, 9(7), e2624615. https://doi.org/10.1001/jamanetworkopen.2026.24615

Vancouver

Gangaram Panday SSG, van Klaveren D, Lagarde SM, van der Wilk BJ, Eyck BM, Rosman C, et al. Surveillance vs Standard Surgery and Cost-Effectiveness After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. JAMA Network Open. 2026;9(7):e2624615. doi:10.1001/jamanetworkopen.2026.24615

BibTeX
@article{GangaramPanday2026,
  author = {Gangaram Panday, Sanjiv S G and van Klaveren, David and Lagarde, Sjoerd M and van der Wilk, Berend J and Eyck, Ben M and Rosman, Camiel and Noordman, Bo J and Valkema, Maria J and Bisseling, Tanya M and Coene, Peter-Paul L O and Dekker, Jan Willem T and van Det, Marc J and van Dieren, Jolanda M and Doukas, Michail and van Esser, Stijn and Fiets, W Edward and Hartgrink, Henk H and Heisterkamp, Joos and Hol, Lieke and Klarenbeek, Bastiaan and Kouw, Eva and Kouwenhoven, Ewout A and Luyer, Misha D and Mostert, Bianca and Nieuwenhuijzen, Grard A P and Oostenbrug, Liekele E and Oude Voshaar, Martijn and Pierie, Jean-Pierre and van Sandick, Johanna W and Sosef, Meindert N and Spaander, Manon C W and Steyerberg, Ewout W and Valkema, Roelf and van der Zaag, Edwin S and van Lanschot, J Jan B and Lingsma, Hester F and Wijnhoven, Bas P L and Surgery as Needed for Oesophageal Cancer (SANO) Study Group, Surgery as Needed for Oesophageal Cancer (SANO) Study Group},
  title = {Surveillance vs Standard Surgery and Cost-Effectiveness After Neoadjuvant Chemoradiotherapy for Esophageal Cancer},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {7},
  pages = {e2624615},
  doi = {10.1001/jamanetworkopen.2026.24615}
}
Kostenlos starten →